Shots:
- ClearNote Health has received the UKCA certification for its Avantect Multi-Cancer & Ovarian Cancer tests to detect multiple cancers & support early diagnosis of ovarian cancer, respectively
- The Multi-Cancer Detection Test screens multiple cancers from a simple blood sample using 5-hydroxymethylcytosine & genomic biomarkers in cell-free DNA, & was selected for the NCI-funded Vanguard Study enrolling ~24,000 pts
- The Ovarian Cancer Test helps early cancer detection in high-risk women, incl. those with BRCA1/2, Lynch syndrome, or strong family history, using ClearNote Health’s Virtuoso epigenomics platform to detect abnormal signals associated with ovarian cancer in cell-free DNA
Ref: ClearNote Health | Image: ClearNote Health | Press Release
Related News:- BMS Reports the P-III (EXCALIBER-RRMM) Trial Data of Iberdomide Regimen to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
